-

Bone Biologics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced that Jeffrey Frelick, the Company’s president and chief executive officer, has been invited to present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28 - 30, 2022. A pre-recorded presentation will be available for 72 hours beginning Monday, March 28th at 9:00 a.m. Eastern time. Interested parties may access a webcast of the presentation on the investor relations section of the Company’s website and at this link.

The conference will be live on M-Vest. To attend, sign up here to become an M-Vest member.

About Bone Biologics

Bone Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking groundbreaking work with select strategic partners, building on unprecedented research on the Nell-1 protein that has produced a significant number of studies and publications in peer reviewed scientific literature. Bone Biologics is currently focusing its development efforts for its bone graft substitute product on bone regeneration in spinal fusion and has rights to trauma and osteoporosis applications. For more information, please visit www.bonebiologics.com.

Contacts

LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com

Industry:

Bone Biologics Corporation

NASDAQ:BBLG
Release Versions
English

Contacts

LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com

More News From Bone Biologics Corporation

Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that President and Chief Executive Officer Jeffrey Frelick has issued the following letter to stockholders. To My Fellow Stockholders: I am pleased to provide a progress report on Bone Biologics’ development of NB1 and to review our expected milestones for the coming year, including the anticipated com...

Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, President and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025. Management will be available during the conference for in-person and virtual one-on-one meetings. Institutional investors and in...

Bone Biologics Announces Closing of $5.0 Million Public Offering

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares o...
Back to Newsroom